1. Scrip
  2. >>Therapy Areas

Lilly/AstraZeneca's Lanabecestat Becomes Latest BACE Inhibitor Casualty

 
• By Eleanor Malone

Just weeks after Johnson & Johnson halted development of its BACE inhibitor for Alzheimer's and a few months after Merck & Co failed at Phase III, Lilly and AstraZeneca end trials of lanabecestat.

magnetic resonance image (MRI) of the brain human

AstraZeneca PLC and Eli Lilly & Co. are to discontinue Phase III trials of their oral beta-site amyloid precursor protein cleaving enzyme (BACE) inhibitor lanabecestat in Alzheimer's disease. The two trials, one in early Alzheimer's and the other in mild Alzheimer's dementia, were stopped for futility on the recommendation of an independent data monitoring committee, which said they were unlikely to meet their primary endpoints on completion.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Seven Up For Sanofi and Regeneron With Dupixent CSU Approval

 
• By Kevin Grogan

The IL-4/IL-13 inhibitor has been approved in the US as the first targeted therapy in over a decade for chronic itching.

Lilly Scores With Orforglipron In Diabetes, Generating Excitement For Obesity

 
• By Alaric DeArment

The company announced positive topline results for the oral GLP-1 drug in type 2 diabetes that beat expectations.

In Brief: BriaCell’s Breast Cancer Cell Therapy Boosts Survival In Phase II

 
• By Sushmita Panda

BriaCell announced its cell therapy Bria-IMT plus checkpoint inhibitors bested Gilead’s Trodelvy in a Phase II trial in HR+ breast cancer; a Phase III trial is enrolling.